Does the media refer more to EWTX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 18 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 36 mentions for Jazz Pharmaceuticals and 18 mentions for Edgewise Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.53 beat Edgewise Therapeutics' score of -0.24 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 11 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EWTX or ELAN?

In the previous week, Elanco Animal Health had 13 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 31 mentions for Elanco Animal Health and 18 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 0.77 beat Edgewise Therapeutics' score of -0.24 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 11 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CORT or EWTX?

In the previous week, Corcept Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 18 mentions for Edgewise Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Edgewise Therapeutics' score of -0.24 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AXSM or EWTX?

In the previous week, Axsome Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Axsome Therapeutics and 18 mentions for Edgewise Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Edgewise Therapeutics' score of -0.24 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer EWTX or RDY?

Edgewise Therapeutics presently has a consensus target price of $48.75, indicating a potential upside of 11.81%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor EWTX or RDY?

In the previous week, Edgewise Therapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Edgewise Therapeutics' score of -0.24 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Edgewise Therapeutics (EWTX) Competitors

$43.58 +0.06 (+0.13%)

As of 12:24 PM Eastern

Compare

EWTX vs. JAZZ, ELAN, CORT, AXSM, and RDY

Should you buy Edgewise Therapeutics stock or one of its competitors? MarketBeat compares Edgewise Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edgewise Therapeutics include Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceuticals" industry.

How does Edgewise Therapeutics compare to Jazz Pharmaceuticals?

Edgewise Therapeutics (NASDAQ:EWTX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Edgewise Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Edgewise Therapeutics presently has a consensus price target of $48.75, suggesting a potential upside of 11.81%. Jazz Pharmaceuticals has a consensus price target of $272.74, suggesting a potential upside of 5.67%. Given Edgewise Therapeutics' higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Edgewise Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Jazz Pharmaceuticals	$4.60B	3.64	-$356.15M	$14.50	17.80

In the previous week, Jazz Pharmaceuticals had 18 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 36 mentions for Jazz Pharmaceuticals and 18 mentions for Edgewise Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.53 beat Edgewise Therapeutics' score of -0.24 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	11 Very Positive mention(s)	7 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Edgewise Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Elanco Animal Health?

Edgewise Therapeutics (NASDAQ:EWTX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Edgewise Therapeutics currently has a consensus target price of $48.75, indicating a potential upside of 11.81%. Elanco Animal Health has a consensus target price of $29.09, indicating a potential upside of 32.35%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Edgewise Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Elanco Animal Health	$4.72B	2.33	-$232M	-$0.41	N/A

In the previous week, Elanco Animal Health had 13 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 31 mentions for Elanco Animal Health and 18 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 0.77 beat Edgewise Therapeutics' score of -0.24 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	11 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Elanco Animal Health	-3.96%	8.13%	3.99%

Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

97.5% of Elanco Animal Health shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Corcept Therapeutics has a net margin of 6.52% compared to Edgewise Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Corcept Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.23	$99.65M	$0.42	272.14
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Corcept Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 18 mentions for Edgewise Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Edgewise Therapeutics' score of -0.24 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Corcept Therapeutics currently has a consensus price target of $119.17, suggesting a potential upside of 4.26%. Edgewise Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 11.81%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Corcept Therapeutics beats Edgewise Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Axsome Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 19 mentions for Axsome Therapeutics and 18 mentions for Edgewise Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Edgewise Therapeutics' score of -0.24 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics currently has a consensus target price of $265.55, suggesting a potential upside of 22.40%. Edgewise Therapeutics has a consensus target price of $48.75, suggesting a potential upside of 11.81%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edgewise Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.49	-$183.17M	-$3.73	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Axsome Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Edgewise Therapeutics' return on equity of -39.01% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summary

Axsome Therapeutics beats Edgewise Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Edgewise Therapeutics (NASDAQ:EWTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Edgewise Therapeutics presently has a consensus target price of $48.75, indicating a potential upside of 11.81%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Edgewise Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Edgewise Therapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Edgewise Therapeutics' score of -0.24 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Dr. Reddy's Laboratories	$3.58B	2.82	$456M	$0.44	27.44

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Edgewise Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Edgewise Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.77B	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-23.73	788.46	269.91	24.87
Price / Sales	N/A	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	8.84	10.37	11.40	6.45
Net Income	-$167.79M	$2.77B	$3.45B	$347.50M
7 Day Performance	13.60%	2.26%	3.66%	3.77%
1 Month Performance	-3.98%	-1.28%	-0.49%	-0.40%
1 Year Performance	243.86%	191.26%	77.51%	23.55%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	2.1209 of 5 stars	$43.58 +0.1%	$48.75 +11.9%	+243.2%	$4.73B	N/A	N/A	60	News Coverage Earnings Report Analyst Revision
JAZZ Jazz Pharmaceuticals	3.1558 of 5 stars	$261.62 +4.0%	$272.74 +4.2%	+130.5%	$15.80B	$4.27B	N/A	2,890	Earnings Report High Trading Volume
ELAN Elanco Animal Health	4.3501 of 5 stars	$25.56 -0.6%	$28.73 +12.4%	+32.8%	$12.85B	$4.72B	26.25	9,400	Earnings Report
CORT Corcept Therapeutics	2.9387 of 5 stars	$109.80 -2.7%	$119.17 +8.5%	+53.2%	$12.19B	$761.41M	261.43	300
AXSM Axsome Therapeutics	3.5152 of 5 stars	$212.17 +0.5%	$261.29 +23.1%	+103.0%	$10.86B	$638.50M	N/A	380	News Coverage Earnings Report Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. JAZZ, ELAN, CORT, AXSM, and RDY

How does Edgewise Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Summary

How does Edgewise Therapeutics compare to Corcept Therapeutics?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Summary

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. JAZZ, ELAN, CORT, AXSM, and RDY

How does Edgewise Therapeutics compare to Jazz Pharmaceuticals?

Is EWTX or JAZZ more profitable?

Do analysts rate EWTX or JAZZ?

Which has more risk & volatility, EWTX or JAZZ?

Which has stronger valuation & earnings, EWTX or JAZZ?

Does the media refer more to EWTX or JAZZ?

Do institutionals & insiders hold more shares of EWTX or JAZZ?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Do analysts rate EWTX or ELAN?

Which has higher earnings and valuation, EWTX or ELAN?

Does the media refer more to EWTX or ELAN?

Is EWTX or ELAN more profitable?

Which has more risk and volatility, EWTX or ELAN?

Do institutionals & insiders have more ownership in EWTX or ELAN?

Summary

How does Edgewise Therapeutics compare to Corcept Therapeutics?

Is CORT or EWTX more profitable?

Which has preferable valuation & earnings, CORT or EWTX?

Does the media prefer CORT or EWTX?

Which has more volatility and risk, CORT or EWTX?

Do analysts recommend CORT or EWTX?

Do institutionals and insiders hold more shares of CORT or EWTX?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Does the media refer more to AXSM or EWTX?

Do analysts recommend AXSM or EWTX?

Do insiders and institutionals hold more shares of AXSM or EWTX?

Which has preferable earnings and valuation, AXSM or EWTX?

Which has more volatility & risk, AXSM or EWTX?

Is AXSM or EWTX more profitable?

Summary

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts prefer EWTX or RDY?

Does the media favor EWTX or RDY?

Which has preferable valuation & earnings, EWTX or RDY?

Is EWTX or RDY more profitable?

Which has more volatility and risk, EWTX or RDY?

Do insiders and institutionals believe in EWTX or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools